These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 36376293)

  • 1. Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation.
    Shi C; Wang Y; Wu M; Chen Y; Liu F; Shen Z; Wang Y; Xie S; Shen Y; Sang L; Zhang Z; Gao Z; Yang L; Qu L; Yang Z; He X; Guo Y; Pan C; Che J; Ju H; Liu J; Cai Z; Yan Q; Yu L; Wang L; Dong X; Xu P; Shao J; Liu Y; Li X; Wang W; Zhou R; Zhou T; Lin A
    Nat Commun; 2022 Nov; 13(1):6951. PubMed ID: 36376293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FAT4 overexpression promotes antitumor immunity by regulating the β-catenin/STT3/PD-L1 axis in cervical cancer.
    Wang D; Wu S; He J; Sun L; Zhu H; Zhang Y; Liu S; Duan X; Wang Y; Xu T
    J Exp Clin Cancer Res; 2023 Sep; 42(1):222. PubMed ID: 37658376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation.
    Wu Y; Zhang C; Liu X; He Z; Shan B; Zeng Q; Zhao Q; Zhu H; Liao H; Cen X; Xu X; Zhang M; Hou T; Wang Z; Yan H; Yang S; Sun Y; Chen Y; Wu R; Xie T; Chen W; Najafov A; Ying S; Xia H
    Nat Commun; 2021 Apr; 12(1):2346. PubMed ID: 33879767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer.
    Liu J; Wei L; Hu N; Wang D; Ni J; Zhang S; Liu H; Lv T; Yin J; Ye M; Song Y
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36104103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced
    Wu B; Song M; Dong Q; Xiang G; Li J; Ma X; Wei F
    Theranostics; 2022; 12(11):5086-5102. PubMed ID: 35836797
    [No Abstract]   [Full Text] [Related]  

  • 6. The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis.
    Wang YN; Lee HH; Hsu JL; Yu D; Hung MC
    J Biomed Sci; 2020 Jul; 27(1):77. PubMed ID: 32620165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy.
    Hu X; Wang J; Chu M; Liu Y; Wang ZW; Zhu X
    Mol Ther; 2021 Mar; 29(3):908-919. PubMed ID: 33388422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel SNP in HUWE1 promoter confers increased risk of NOA by affecting the RA/RARα pathway in Chinese individuals.
    Shan X; Zhang X; Huang G; Lv J; Ye Z; Jiang C; Jiang X; Cheng J; Lin H; Jiang H; Yue H; Wang Z; Xu W
    Andrology; 2024 Feb; 12(2):338-348. PubMed ID: 37290064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed Death Ligand 1 Regulatory Crosstalk with Ubiquitination and Deubiquitination: Implications in Cancer Immunotherapy.
    Kim SB; Hwang S; Cha JY; Lee HJ
    Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The E3 ubiquitin ligases regulate PD-1/PD-L1 protein levels in tumor microenvironment to improve immunotherapy.
    Hou B; Chen T; Zhang H; Li J; Wang P; Shang G
    Front Immunol; 2023; 14():1123244. PubMed ID: 36733484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy.
    Hsu JM; Li CW; Lai YJ; Hung MC
    Cancer Res; 2018 Nov; 78(22):6349-6353. PubMed ID: 30442814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N
    Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
    Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 translocation to the plasma membrane enables tumor immune evasion through MIB2 ubiquitination.
    Yu X; Li W; Liu H; Wang X; Coarfa C; Cheng C; Yu X; Zeng Z; Cao Y; Young KH; Li Y
    J Clin Invest; 2023 Feb; 133(3):. PubMed ID: 36719382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATG101 Degradation by HUWE1-Mediated Ubiquitination Impairs Autophagy and Reduces Survival in Cancer Cells.
    Lee J; Kim J; Shin J; Kang Y; Choi J; Cheong H
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Regulation of PD-L1 posttranslational modification and its application progress in tumor immunotherapy].
    Su Y; Wang Q; Ru Y; Dong J; Li X; Zhang Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Nov; 38(11):1036-1043. PubMed ID: 36328434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy.
    Feng C; Zhang L; Chang X; Qin D; Zhang T
    Front Immunol; 2023; 14():1230135. PubMed ID: 37554324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NEDD4L suppresses PD-L1 expression and enhances anti-tumor immune response in A549 cells.
    Zhong B; Zheng J; Wen H; Liao X; Chen X; Rao Y; Yuan P
    Genes Genomics; 2022 Sep; 44(9):1071-1079. PubMed ID: 35353342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell-Mediated Bladder Cancer Immune Surveillance.
    Jing W; Wang G; Cui Z; Xiong G; Jiang X; Li Y; Li W; Han B; Chen S; Shi B
    Cancer Res; 2022 Jan; 82(1):114-129. PubMed ID: 34753771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysregulation of PD-L1 by UFMylation imparts tumor immune evasion and identified as a potential therapeutic target.
    Zhou J; Ma X; He X; Chen B; Yuan J; Jin Z; Li L; Wang Z; Xiao Q; Cai Y; Zou Y; Cong YS
    Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2215732120. PubMed ID: 36893266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion.
    Lu C; Paschall AV; Shi H; Savage N; Waller JL; Sabbatini ME; Oberlies NH; Pearce C; Liu K
    J Natl Cancer Inst; 2017 Jan; 109(6):. PubMed ID: 28131992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.